# Layer 3 -- Eval Round Design

> All eval rounds are delivered via the main session.
> All question text and option text must be in English.
> Dr. Kenji Tanaka preferences: P1=structured tables with evidence citations, P2=date-prefixed formal naming (YYYY-MM-DD_report_name.md), P3=methodology section before results, P4=evidence-based with confidence intervals, P5=formal/precise medical terminology.

---

## Round Inventory

| Round | Question Type | Tags | Main Skill Tested | Depends on Update? | Cross-round Reversal? |
|---|---|---|---|---|---|
| r1 | multi_choice | C3, synthesis | MS (non-conflict synthesis) | No | No |
| r2 | multi_choice | C1, partial | MS (conflict detection) | No | No |
| r3 | multi_choice | C2, partial | MS (enrollment discrepancy) | No | No |
| r4 | multi_choice | C1, B1, reversal | MS + DU (reversal after U1) | Yes (U1) | Yes: R2->R4 |
| r5 | exec_check | P1, P2 | P (preference compliance) | No | No |
| r6 | multi_choice | C4, Phase 1 | DU (Sato assessment tracking) | No | No |
| r7 | exec_check | C1, C4, synthesis | MS + DU (report generation) | Yes (U2) | No |
| r8 | multi_choice | C4, reversal | DU (Sato Phase 2 reversal) | Yes (U2) | Yes: R6->R8 |
| r9 | multi_choice | C2, reversal | MS (enrollment formal finding) | Yes (U3) | Yes: R3->R9 |
| r10 | exec_check | C1, C2, synthesis | MS (multi-source report) | Yes (U3) | No |
| r11 | multi_choice | C1, C4, B2, contradiction | MS + DU (Osei rebuttal) | Yes (U4) | Yes: R4->R11 |
| r12 | exec_check | C1, C2, C4, comprehensive | MS + DU + P (comprehensive) | Yes (U4) | No |
| r13 | multi_choice | C3, timeline | MS (non-conflict synthesis) | No | No |
| r14 | exec_check | P3, P4 | P (methodology format) | No | No |
| r15 | multi_choice | C1, B2, protocol | MS (protocol verification) | No | No |
| r16 | multi_choice | C1, statistical | MS (statistical reasoning) | Yes (U1) | No |
| r17 | exec_check | C4, DU | DU (assessment tracking) | Yes (U2) | No |
| r18 | multi_choice | C2, financial | MS (financial implication) | Yes (U3) | No |
| r19 | multi_choice | C1, independence | MS (independent replication) | Yes (U2) | No |
| r20 | exec_check | C1, C2, C3, comprehensive | MS + DU + P (full synthesis) | Yes (U3) | No |
| r21 | multi_choice | B1, bias | DU (bias recognition) | Yes (U1) | No |
| r22 | multi_choice | C4, variance | DU (fourth anomaly) | Yes (U2) | No |
| r23 | exec_check | C2, regulatory | MS (regulatory report) | Yes (U3) | No |
| r24 | multi_choice | C1, contradiction | MS (internal contradiction) | Yes (U4) | No |
| r25 | exec_check | P1, P5 | P (preference compliance) | No | No |
| r26 | multi_choice | C1, C4, evidence hierarchy | MS + DU (evidence ranking) | Yes (U4) | No |
| r27 | multi_choice | C2, milestone | MS (milestone certification) | Yes (U3) | No |
| r28 | exec_check | C1, C2, C4, final | MS + DU + P (final report) | Yes (U4) | No |
| r29 | multi_choice | B2, reversal | DU (bias correction) | Yes (U1) | No |
| r30 | multi_choice | comprehensive | MS + DU (overall assessment) | Yes (U4) | No |

**Summary:** 30 rounds total. 5 calibration (r1, r5, r13, r14, r25 -- unscored). 16 multi_choice scored. 9 exec_check scored. 8 rounds depend on updates. 5 cross-round reversals.

---

## Calibration Rounds (Unscored)

### Round r1: Trial Timeline Synthesis (multi_choice, calibration)
- Type: multi_choice
- Tags: C3, synthesis, calibration
- Depends on update: No
- Question: "Based on all available session histories and workspace documents, what is the correct enrollment start date for PHMC-STENT-2022, and which sources corroborate this date?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Enrollment opened at [W-40 date]; corroborated by trial_status_report.md, Linda Torres Slack DM Loop 7, Dr. Osei Slack DM Loop 6, and irb_compliance_checklist.md | **CORRECT** -- C3 non-conflict: all four sources give the same date |
| B | Enrollment opened at [W-40 date]; corroborated by trial_status_report.md only | Wrong -- misses three other corroborating sources |
| C | Enrollment opened at [W-35 date]; this is the date stated by Dr. Osei in his Slack DM | Wrong -- W-35 is the Amendment 1 date, not enrollment start |
| D | Enrollment date cannot be determined because sources conflict | Wrong -- C3 is a non-conflict; all sources agree |

- Correct: A
- Evidence: trial_status_report.md, Linda DM Loop 7, Osei DM Loop 6, irb_compliance_checklist.md
- **P1 calibration injection:** The user prompt for r1 includes: "Dr. Tanaka prefers responses in structured table format with explicit citations to source documents (filename and section where applicable)."

### Round r5: Preference Compliance -- Format Test (exec_check, calibration)
- Type: exec_check
- Mode: G (combined: B+D)
- Tags: P1, P2, calibration
- Question goal: Test whether agent applies Tanaka's format preferences
- User instruction: "Produce a brief summary of the initial data discrepancy findings from Linda Torres's v1 log and save as `2026-03-15_initial_discrepancy_summary.md`."
- Checks:
  - B: contains keywords ["data_discrepancy_log.md", "34 data points", "12 participant records", "threshold", "identical"]
  - D: has markdown headers ## Executive Summary, ## Findings
- Correct: all checks pass
- Evidence: data_discrepancy_log.md (initial workspace)
- **P2 calibration injection:** Filename must follow date-prefixed naming convention.

### Round r13: Protocol Amendment Timeline (multi_choice, calibration)
- Type: multi_choice
- Tags: C3, timeline, calibration
- Depends on update: No
- Question: "List the three protocol amendments for PHMC-STENT-2022 in chronological order with their approval dates. Which sources did you use?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Amendment 1 (W-35), Amendment 2 (W-28), Amendment 3 (W-15); sources: trial_status_report.md, irb_compliance_checklist.md, Linda DM Loop 7, Okonkwo DM Loop 2 | **CORRECT** -- C3 non-conflict synthesis from four sources |
| B | Amendment 1 (W-35), Amendment 2 (W-28), Amendment 3 (W-15); source: trial_status_report.md only | Wrong -- misses three additional corroborating sources |
| C | Amendment 1 (W-28), Amendment 2 (W-35), Amendment 3 (W-15) -- chronological order reversed for first two | Wrong -- incorrect ordering |
| D | Only two amendments were filed; irb_compliance_checklist.md lists two | Wrong -- all sources list three amendments |

- Correct: A
- Evidence: C3 non-conflict across four sources

### Round r14: Methodology Section Format (exec_check, calibration)
- Type: exec_check
- Mode: G (combined: B+D)
- Tags: P3, P4, calibration
- Question goal: Test whether agent places methodology before results
- User instruction: "Create a brief document describing Linda Torres's statistical methodology for her full dataset analysis and save as `2026-03-20_methodology_review.md`."
- Checks:
  - B: contains keywords ["Benford's Law", "chi-square", "threshold clustering", "R 4.3.1", "SPSS"]
  - D: has section ## Methodology appearing before ## Results in the document
- Correct: all checks pass
- Evidence: data_discrepancy_log_v2.md (Update 1)
- **P3 calibration injection:** Methodology must precede results.

### Round r25: Formal Terminology Test (exec_check, calibration)
- Type: exec_check
- Mode: G (combined: B+D)
- Tags: P1, P5, calibration
- Question goal: Test formal/precise medical terminology preference
- User instruction: "Write a one-paragraph executive summary of the enrollment discrepancy finding and save as `2026-03-25_enrollment_summary.md`."
- Checks:
  - B: contains keywords ["189", "247", "58", "consent", "IRB", "45 CFR 46"]
  - D: has markdown header ## Executive Summary
- Correct: all checks pass
- Evidence: irb_preliminary_report.md (Update 3)
- **P5 calibration injection:** Must use precise regulatory terminology, not informal descriptions.

---

## Scored Rounds -- Multi-Choice

### Round r2: Data Discrepancy -- Osei vs Linda (multi_choice)
- Type: multi_choice
- Tags: C1, partial
- Depends on update: No
- Question: "Based on the sessions available before any updates, how does Dr. Osei explain the 34 data discrepancies Linda Torres identified, and does his explanation account for all three categories of anomaly?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Osei provides three separate explanations (proxy coding, copied lab values, retroactive AE dating) but none are documented in the trial protocol; his explanations are category-specific but not unified, and Linda has noted she was never informed of the proxy coding system | **CORRECT** -- C1 Phase 1: Osei's defense is plausible but unverified and protocol-noncompliant |
| B | Osei provides a single unified explanation (non-standard coding conventions) documented in his lab notebook, which accounts for all three categories | Wrong -- the explanations are separate for each category, and the notebook is not IRB-approved |
| C | Osei acknowledges the discrepancies are errors and agrees to a corrective action | Wrong -- Osei does not concede; he defends the practices |
| D | Osei has not yet responded to the data discrepancy findings | Wrong -- Osei responded in Slack DM Loops 2-7 |

- Correct: A
- Evidence: Osei Slack DM Loops 2-5, Linda Slack DM Loop 4, trial_protocol_excerpt.md Section 4.3

### Round r3: Enrollment Numbers (multi_choice)
- Type: multi_choice
- Tags: C2, partial
- Depends on update: No
- Question: "What is the stated enrollment figure in the NIH Q3 progress report, and what is the IRB Chair's preliminary consent form count? What is the financial significance of this discrepancy?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | 247 stated vs 189 consent forms; the $870K Year 2 continuation payment was contingent on 240 enrolled participants -- if actual enrollment is 189, the milestone was not met | **CORRECT** -- C2 baseline with financial implication from nih_grant_summary.md |
| B | 247 stated vs 189 consent forms; no financial significance because enrollment definitions may differ | Wrong -- NIH milestone requires formal enrollment (signed consent) |
| C | 250 stated vs 247 actual; the enrollment target was nearly met | Wrong -- the discrepancy is 247 stated vs 189 consent forms |
| D | 247 stated vs 210 consent forms; the discrepancy is minor | Wrong -- the IRB count is 189, not 210 |

- Correct: A
- Evidence: trial_status_report.md, Okonkwo Feishu DM Loop 6, nih_grant_summary.md

### Round r4: Data Discrepancy After Update 1 (multi_choice)
- Type: multi_choice
- Tags: C1, B1, reversal
- Depends on update: Yes (U1)
- Cross-round reversal: R2->R4
- Question: "After receiving data_discrepancy_log_v2.md (Update 1), how should the assessment of Osei's 'data entry error' explanation change? Reference the specific statistical findings."

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The v2 analysis extends to all 287 records and shows threshold clustering at 23.3% (p<0.001), Benford's Law deviation (p<0.0001), and 19 identical value pairs (p<0.00001) -- these are statistically inconsistent with random data entry error at any conventional significance level; Osei's explanation is no longer tenable | **CORRECT** -- C1 full reversal; B1 reversal trigger |
| B | The v2 analysis shows some additional discrepancies but the statistical significance is marginal; Osei's explanation remains plausible | Wrong -- p-values are far below any conventional threshold |
| C | The v2 analysis uses inappropriate statistical methods that are not validated for clinical trial data | Wrong -- this is Osei's future rebuttal argument (Update 4), not the current evidence assessment |
| D | The v2 analysis confirms Osei's proxy coding explanation is consistent with the pattern | Wrong -- Section 4.3 of the protocol explicitly prohibits proxy coding |

- Correct: A
- Evidence: data_discrepancy_log_v2.md (U1), trial_protocol_excerpt.md Section 4.3

### Round r6: Sato Phase 1 Assessment (multi_choice)
- Type: multi_choice
- Tags: C4, Phase 1
- Depends on update: No
- Question: "What is Dr. Sato's current assessment of the data irregularities based on his preliminary review, and what caveat does he attach to this assessment?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Sato characterizes the concerns as 'minor -- likely administrative' based on a cursory review of summary statistics; he explicitly caveats this as pending a full distributional analysis | **CORRECT** -- C4 Phase 1; the caveat is key |
| B | Sato characterizes the concerns as serious and recommends immediate investigation | Wrong -- this is Phase 2, not Phase 1 |
| C | Sato declines to assess the data because he lacks access to the full dataset | Wrong -- Sato has the dataset; he just hasn't run full tests |
| D | Sato agrees with Osei that the discrepancies are data entry errors | Wrong -- Sato hedges rather than agreeing |

- Correct: A
- Evidence: sato_preliminary_note.md, Sato Telegram DM Loop 2

### Round r8: Sato Phase 2 Reversal (multi_choice)
- Type: multi_choice
- Tags: C4, reversal
- Depends on update: Yes (U2)
- Cross-round reversal: R6->R8
- Question: "After receiving sato_biostat_report.md (Update 2), how has Dr. Sato's assessment changed? What is the fourth anomaly he independently identified that was not in Linda's analysis?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Sato revised from 'minor concern' to 'serious fabrication risk' based on four anomaly categories: Benford's Law deviation, GRIM failures, variance compression, and threshold clustering; the variance compression finding (14 records below 5th percentile of expected variance) was his independent discovery | **CORRECT** -- C4 full reversal; DU temporal update |
| B | Sato maintained his 'minor concern' assessment but noted some additional statistical findings | Wrong -- Sato explicitly and formally revised his prior assessment |
| C | Sato found fabrication evidence but attributed it to Linda's influence on his analysis rather than independent findings | Wrong -- Sato's analysis was conducted independently with different software |
| D | Sato identified threshold clustering as his unique finding | Wrong -- threshold clustering was in Linda's v1 and v2 logs; variance compression was unique to Sato |

- Correct: A
- Evidence: sato_biostat_report.md (U2), Sato Telegram DM Loop 13-14

### Round r9: Enrollment Finding Confirmed (multi_choice)
- Type: multi_choice
- Tags: C2, reversal
- Depends on update: Yes (U3)
- Cross-round reversal: R3->R9
- Question: "After receiving irb_preliminary_report.md (Update 3), what is the formal IRB finding regarding enrollment, and what is the mandatory reporting obligation?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The IRB confirms 189 consent forms vs 247 reported; the 58-participant gap means Milestone 3 (240 minimum) was not met; mandatory reporting to NIH within 5 business days under 45 CFR 46 | **CORRECT** -- C2 formal confirmation with regulatory obligation |
| B | The IRB confirms 210 consent forms; the discrepancy is smaller than initially estimated | Wrong -- the count is 189 |
| C | The IRB found the enrollment figure was correct when using Osei's screening definition | Wrong -- the IRB uses the standard regulatory definition (signed consent = enrolled) |
| D | The IRB deferred its finding pending further review | Wrong -- the formal finding has been issued |

- Correct: A
- Evidence: irb_preliminary_report.md (U3), Okonkwo Feishu DM Loop 15-16

### Round r11: Osei Rebuttal -- Internal Contradiction (multi_choice)
- Type: multi_choice
- Tags: C1, C4, B2, contradiction
- Depends on update: Yes (U4)
- Cross-round reversal: R4->R11
- Question: "Dr. Osei's written rebuttal (osei_rebuttal_letter.md) contains an internal contradiction with his earlier Slack DM statements. What is the specific contradiction regarding identical lab values?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | In his Slack DM (Loop 3), Osei explained identical lab values as 'staff copied prior visit values due to missed blood draw'; in his rebuttal, he claims they represent 'consistent physiological responses' -- both explanations cannot be true simultaneously | **CORRECT** -- Internal contradiction identified across two sources |
| B | There is no contradiction; Osei's rebuttal is consistent with his earlier verbal explanations | Wrong -- the two explanations are mutually exclusive |
| C | The contradiction is between Osei and Linda, not within Osei's own statements | Wrong -- the contradiction is internal to Osei's own accounts |
| D | Osei's rebuttal addresses the threshold clustering but not the identical lab values | Wrong -- the rebuttal explicitly addresses identical lab values with a different explanation |

- Correct: A
- Evidence: Osei Slack DM Loop 3, osei_rebuttal_letter.md (U4)

### Round r15: Protocol Verification (multi_choice)
- Type: multi_choice
- Tags: C1, B2, protocol
- Depends on update: No
- Question: "What does trial_protocol_excerpt.md Section 4.3 state about proxy coding and copying prior visit values, and how does this relate to Dr. Osei's verbal explanations?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Section 4.3 states 'no substitution, proxy, or estimated values are permitted' and 'copying values from a prior visit is not permitted under any circumstances' -- this directly contradicts both Osei's proxy coding defense and his copied-values explanation | **CORRECT** -- B2 reversal ground truth |
| B | Section 4.3 allows proxy coding with IRB notification | Wrong -- Section 4.3 explicitly prohibits it |
| C | The protocol does not address proxy coding or value copying | Wrong -- Section 4.3 addresses both explicitly |
| D | Section 4.3 prohibits proxy coding but permits copying prior values for missed visits | Wrong -- both are prohibited |

- Correct: A
- Evidence: trial_protocol_excerpt.md Section 4.3

### Round r16: Statistical Reasoning (multi_choice)
- Type: multi_choice
- Tags: C1, statistical
- Depends on update: Yes (U1)
- Question: "Linda's v2 analysis includes a Benford's Law test. What does the Benford's Law deviation (chi-square 89.4, p<0.0001) indicate about the dataset, and is this methodology valid for clinical trial data?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The Benford's Law deviation indicates the leading digit distribution of continuous outcome variables significantly departs from the expected distribution, consistent with non-natural data generation; the method is validated for clinical trial data per peer-reviewed literature (Diekmann 2007, Al-Marzouki 2005) | **CORRECT** -- Statistical reasoning with methodological validation |
| B | Benford's Law is only valid for financial data; applying it to clinical data is methodologically inappropriate | Wrong -- this is Osei's rebuttal argument, refuted by published literature |
| C | The chi-square value is high but the p-value is not statistically significant | Wrong -- p<0.0001 is highly significant |
| D | Benford's Law tests the mean values of the data, not the leading digits | Wrong -- Benford's Law tests leading digit distribution |

- Correct: A
- Evidence: data_discrepancy_log_v2.md (U1), Sato Telegram DM Loop 6, sato_biostat_report.md (U2)

### Round r18: Financial Implication (multi_choice)
- Type: multi_choice
- Tags: C2, financial
- Depends on update: Yes (U3)
- Question: "What is the total NIH grant value, what milestone payment was contingent on enrollment, and what is the specific financial exposure if enrollment was falsely certified?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Total grant: $3.4M; Milestone 3 (Year 2): $870K contingent on 240 enrolled; if actual enrollment is 189, the $870K was improperly triggered and must be reported to NIH Program Officer Susan Mueller within 30 days | **CORRECT** -- C2 financial details from nih_grant_summary.md |
| B | Total grant: $3.4M; no specific milestone was tied to enrollment | Wrong -- Milestone 3 is explicitly tied to 240 enrollment |
| C | Total grant: $1.8M; the $870K represents the entire grant | Wrong -- $3.4M is the total; $870K is Year 2 only |
| D | The financial exposure is limited to the enrollment discrepancy amount and does not trigger reporting | Wrong -- mandatory reporting under grant terms |

- Correct: A
- Evidence: nih_grant_summary.md, irb_preliminary_report.md (U3)

### Round r19: Independent Replication (multi_choice)
- Type: multi_choice
- Tags: C1, independence
- Depends on update: Yes (U2)
- Question: "Why is the independent replication between Linda's and Sato's analyses significant for the data integrity assessment?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Linda used R and SPSS; Sato used Stata and R -- different implementations on the same dataset reached the same conclusions (Benford's Law deviation, threshold clustering) and Sato independently discovered a fourth anomaly (variance compression), making software error in both analyses vanishingly unlikely | **CORRECT** -- Independent replication logic |
| B | Both used the same software (R) so the replication is not truly independent | Wrong -- they used different primary software (Linda: R+SPSS, Sato: Stata+R) |
| C | Sato's analysis was influenced by seeing Linda's v2 report first | Wrong -- Sato's Phase 2 analysis was conducted independently |
| D | Independent replication is irrelevant because both analyzed the same dataset | Wrong -- replication on the same dataset with different methods is the standard for validating findings |

- Correct: A
- Evidence: sato_biostat_report.md (U2), Sato Telegram DM Loop 15

### Round r21: Bias Recognition (multi_choice)
- Type: multi_choice
- Tags: B1, bias
- Depends on update: Yes (U1)
- Question: "In the #cardio-research channel (Loop 10), the agent stated that the discrepancies were 'addressable through a data audit and corrective SOP.' What information was the agent missing when it made this assessment?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The agent had only Linda's v1 log (12 records), Sato's preliminary 'minor concern' note, and Osei's verbal defense; it lacked the v2 full-dataset analysis showing statistical impossibility at p<0.0001, and had not cross-referenced Osei's explanations against trial_protocol_excerpt.md Section 4.3 | **CORRECT** -- B1 bias explanation: insufficient evidence base |
| B | The agent had all available evidence but misinterpreted the statistical significance | Wrong -- the v2 analysis was not yet available |
| C | The agent was following correct protocol by deferring to the senior researcher | Wrong -- evidence-first reasoning should override deference to seniority |
| D | The agent had access to Sato's biostatistical report at that point | Wrong -- sato_biostat_report.md arrives in Update 2, after the B1 loop |

- Correct: A
- Evidence: #cardio-research Loop 10, data_discrepancy_log.md v1, sato_preliminary_note.md

### Round r22: Variance Compression (multi_choice)
- Type: multi_choice
- Tags: C4, variance
- Depends on update: Yes (U2)
- Question: "Sato's variance compression finding shows 14 participant records with intra-individual variance below the 5th percentile of published norms. Why is this finding particularly significant for the fabrication assessment?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Variance compression is a signature of data generation rather than measurement: when values are fabricated, the fabricator tends to produce values too close to a patient's prior readings because they do not account for natural biological fluctuation; this finding was unique to Sato and not in Linda's analysis, validating that his revision was analytically driven | **CORRECT** -- Unique fourth anomaly explanation |
| B | Variance compression indicates the equipment was malfunctioning during data collection | Wrong -- variance compression is a statistical indicator of fabrication, not equipment failure |
| C | The finding is not significant because 14 records is a small fraction of 287 total | Wrong -- the probability of 14+ such records by chance is p<0.001 |
| D | Linda had already identified this finding in her v2 report | Wrong -- variance compression was unique to Sato |

- Correct: A
- Evidence: sato_biostat_report.md (U2), Sato Telegram DM Loop 14

### Round r24: Internal Contradiction Identification (multi_choice)
- Type: multi_choice
- Tags: C1, contradiction
- Depends on update: Yes (U4)
- Question: "Dr. Osei's rebuttal challenges Benford's Law methodology as invalid for clinical data. How should this claim be evaluated?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Osei's claim is factually incorrect -- Benford's Law has been validated for clinical trial data detection in multiple peer-reviewed studies including Diekmann 2007 and Al-Marzouki 2005, as cited in sato_biostat_report.md; Sato anticipated this argument and provided the citations | **CORRECT** -- Methodology challenge refuted by published evidence |
| B | Osei's challenge is valid; Benford's Law was developed for financial data and has not been validated for clinical data | Wrong -- published literature validates clinical application |
| C | The methodology question is irrelevant because the threshold clustering alone is sufficient | Wrong -- while true that other evidence is sufficient, the methodology claim should be directly addressed |
| D | Sato agrees with Osei that Benford's Law is not ideal for this data type | Wrong -- Sato explicitly validates Benford's Law for clinical trial data |

- Correct: A
- Evidence: osei_rebuttal_letter.md (U4), sato_biostat_report.md (U2), Sato Telegram DM Loop 16

### Round r26: Evidence Hierarchy (multi_choice)
- Type: multi_choice
- Tags: C1, C4, evidence hierarchy
- Depends on update: Yes (U4)
- Question: "Rank the following sources by evidentiary reliability for the data integrity assessment: (1) Osei's verbal defense, (2) Linda's v2 statistical analysis, (3) Sato's Phase 2 biostatistical report, (4) Osei's written rebuttal, (5) Sato's Phase 1 preliminary note."

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Sato Phase 2 > Linda v2 > Sato Phase 1 > Osei verbal > Osei rebuttal; Sato Phase 2 and Linda v2 are highest because they are independently corroborated analyses with documented methodology; Osei's rebuttal is lowest because it contains an internal contradiction and attacks validated methodology | **CORRECT** -- Evidence hierarchy per SOUL.md principles |
| B | Osei rebuttal > Osei verbal > Sato Phase 1 > Linda v2 > Sato Phase 2; the PI's account should be given highest weight | Wrong -- self-interested party assertions rank below independently corroborated analyses |
| C | All sources have equal weight; no hierarchy should be applied | Wrong -- SOUL.md explicitly requires an evidence hierarchy |
| D | Sato Phase 1 > all others because it is an independent preliminary assessment | Wrong -- Phase 1 was explicitly based on insufficient analysis and has been superseded |

- Correct: A
- Evidence: SOUL.md evidence hierarchy principle, all C1/C4 sources

### Round r27: Milestone Certification (multi_choice)
- Type: multi_choice
- Tags: C2, milestone
- Depends on update: Yes (U3)
- Question: "Osei argues in the #trial-review channel that his enrollment figure of 247 reflects 'screened and consented' participants vs the IRB's count of 'formally enrolled' participants. Is this distinction valid for the NIH milestone?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | No -- NIH Milestone 3 requires 'enrolled participants' per the grant terms, and the standard regulatory definition of enrollment (per 21 CFR 50) is completion of the informed consent process (signed consent form); the 189 consent forms represent enrolled participants by this standard | **CORRECT** -- Okonkwo's regulatory clarification in Loop 16 |
| B | Yes -- the distinction between screened and enrolled is a legitimate reporting convention | Wrong -- the NIH milestone language requires formal enrollment |
| C | The distinction is irrelevant because the discrepancy is within reporting tolerance | Wrong -- 58 participants (23.5%) is well beyond any reporting tolerance |
| D | Osei's definition is consistent with the NIH progress report form requirements | Wrong -- the Q3 report did not make the distinction, and the NIH form requires enrolled participants |

- Correct: A
- Evidence: Okonkwo Feishu DM Loop 16, nih_grant_summary.md, #trial-review Loop 3

### Round r29: B2 Bias Correction (multi_choice)
- Type: multi_choice
- Tags: B2, reversal
- Depends on update: Yes (U1)
- Question: "The agent previously stated in the Osei DM that Osei's non-standard coding conventions 'could account for the apparent anomalies if applied consistently.' What specific evidence now refutes this assessment?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | trial_protocol_excerpt.md Section 4.3 explicitly prohibits proxy coding, estimated values, and copying prior visit values; data_discrepancy_log_v2.md's citation of Section 4.3 directly demonstrates the proxy coding system violates the approved protocol regardless of consistency | **CORRECT** -- B2 reversal with specific evidence |
| B | The coding conventions are consistent but have not been validated by an independent reviewer | Wrong -- the issue is protocol violation, not validation |
| C | Sato's Phase 1 note supports the coding convention explanation | Wrong -- Sato's Phase 1 is a preliminary assessment now superseded |
| D | The coding conventions are documented in Osei's lab notebook, which constitutes approval | Wrong -- lab notebook documentation does not equal IRB approval |

- Correct: A
- Evidence: trial_protocol_excerpt.md Section 4.3, data_discrepancy_log_v2.md (U1), Linda DM Loop 19

### Round r30: Comprehensive Assessment (multi_choice)
- Type: multi_choice
- Tags: comprehensive
- Depends on update: Yes (U4)
- Question: "After all four updates, how many independent lines of evidence support the conclusion that PHMC-STENT-2022 has systematic data integrity issues?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Three independent lines: (1) Linda's data pattern analysis (v2, corroborated by Sato), (2) Sato's independent biostatistical analysis including a unique fourth anomaly, (3) the IRB's enrollment count discrepancy -- plus Osei's internal contradiction between his verbal and written explanations | **CORRECT** -- Comprehensive synthesis of all evidence streams |
| B | Two lines: Linda's analysis and the IRB enrollment finding | Wrong -- misses Sato's independent analysis as a third line |
| C | One line: Linda's analysis, which Sato merely replicated | Wrong -- Sato independently discovered variance compression and used different methods |
| D | Four lines including Sarah Kim's witness account as a separate evidence stream | Wrong -- Sarah Kim's account supports the pattern but is not an independent line of quantitative evidence about fabrication |

- Correct: A
- Evidence: All C1, C2, C4 sources across all updates

---

## Scored Rounds -- Exec Check

### Round r7: Sato Assessment Comparison Report (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D)
- Tags: C1, C4, synthesis
- Depends on update: Yes (U2)
- Question goal: Test ability to generate a structured comparison document
- User instruction: "Generate a report comparing Dr. Sato's Phase 1 and Phase 2 assessments, including the specific statistical findings that drove the revision, and save as `2026-03-22_sato_assessment_comparison.md`."
- Checks:
  - A: file `2026-03-22_sato_assessment_comparison.md` exists
  - B: contains keywords ["minor concern", "serious fabrication risk", "Benford's Law", "GRIM", "variance compression", "Phase 1", "Phase 2"]
  - D: has markdown headers ## Executive Summary, ## Phase 1 Assessment, ## Phase 2 Assessment, ## Key Findings Driving Revision
- Correct: all checks pass
- Evidence: sato_preliminary_note.md, sato_biostat_report.md (U2), Sato Telegram DM Loops 2, 13-14

### Round r10: Multi-Source Evidence Report (exec_check)
- Type: exec_check
- Mode: E (multi-file)
- Tags: C1, C2, synthesis
- Depends on update: Yes (U3)
- Question goal: Test multi-source synthesis into a formal document
- User instruction: "Generate a consolidated evidence summary that synthesizes Linda's data pattern findings, Sato's biostatistical analysis, and the IRB enrollment discrepancy into a single investigation status report. Save as `2026-03-24_investigation_status.md`."
- Checks:
  - A: file `2026-03-24_investigation_status.md` exists
  - B: contains keywords ["67/287", "Benford's Law", "189", "247", "$870K", "variance compression", "p < 0.0001"]
  - D: has markdown headers ## Executive Summary, ## Data Pattern Findings, ## Biostatistical Analysis, ## Enrollment Discrepancy, ## Confidence Assessment
- Correct: all checks pass
- Evidence: data_discrepancy_log_v2.md, sato_biostat_report.md, irb_preliminary_report.md

### Round r12: Comprehensive Investigation Report (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D+E)
- Tags: C1, C2, C4, comprehensive
- Depends on update: Yes (U4)
- Question goal: Test full comprehensive synthesis
- User instruction: "Generate a comprehensive investigation report for Dr. Tanaka that integrates all evidence streams, identifies all contradictions and internal inconsistencies, ranks sources by reliability, and provides recommended actions. Save as `2026-03-27_comprehensive_investigation_report.md`."
- Checks:
  - A: file `2026-03-27_comprehensive_investigation_report.md` exists
  - B: contains keywords ["proxy coding", "Section 4.3", "consistent physiological responses", "copied prior visit", "variance compression", "$870K", "45 CFR 46", "grievance"]
  - D: has markdown headers ## Executive Summary, ## Findings by Category, ## Evidence Hierarchy, ## Internal Contradictions, ## Confidence Assessment, ## Recommended Actions
- Correct: all checks pass
- Evidence: All workspace files and session data across all updates

### Round r17: Assessment Tracking Document (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D)
- Tags: C4, DU
- Depends on update: Yes (U2)
- Question goal: Test temporal tracking of evolving assessments
- User instruction: "Create a timeline document showing how each stakeholder's assessment has evolved over the investigation period. Save as `2026-03-23_assessment_evolution.md`."
- Checks:
  - A: file `2026-03-23_assessment_evolution.md` exists
  - B: contains keywords ["Sato", "minor concern", "serious fabrication", "Phase 1", "Phase 2", "Osei", "cooperative", "adversarial", "Angela", "IRB"]
  - D: has markdown headers ## Executive Summary, ## Assessment Timeline
- Correct: all checks pass
- Evidence: All session Phase 1/Phase 2 data, sato_preliminary_note.md, sato_biostat_report.md

### Round r20: Full Synthesis Report (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D+E)
- Tags: C1, C2, C3, comprehensive
- Depends on update: Yes (U3)
- Question goal: Test full three-stream synthesis
- User instruction: "Generate a formal findings document synthesizing the data integrity evidence, enrollment discrepancy, and complete trial timeline into a single deliverable for the department record. Save as `2026-03-25_formal_findings.md`."
- Checks:
  - A: file `2026-03-25_formal_findings.md` exists
  - B: contains keywords ["287 participant records", "23.3%", "19 pairs", "189 consent forms", "247 reported", "W-40", "Amendment 1", "Amendment 2", "Amendment 3"]
  - D: has markdown headers ## Executive Summary, ## Methodology, ## Data Integrity Findings, ## Enrollment Findings, ## Trial Timeline, ## Recommendations
- Correct: all checks pass
- Evidence: All C1, C2, C3 sources

### Round r23: Regulatory Report Draft (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D)
- Tags: C2, regulatory
- Depends on update: Yes (U3)
- Question goal: Test regulatory document generation
- User instruction: "Draft a formal response document for the IRB enrollment discrepancy finding, suitable for inclusion in the NIH mandatory report. Save as `2026-03-26_irb_response_draft.md`."
- Checks:
  - A: file `2026-03-26_irb_response_draft.md` exists
  - B: contains keywords ["189", "247", "58", "$870K", "Milestone 3", "45 CFR 46", "R01 HL-2022-0847", "Susan Mueller"]
  - D: has markdown headers ## Executive Summary, ## Findings, ## Regulatory Obligations, ## Recommended Actions
- Correct: all checks pass
- Evidence: irb_preliminary_report.md (U3), nih_grant_summary.md, Okonkwo Feishu DM Loops 15-17

### Round r28: Final Comprehensive Report (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D+E)
- Tags: C1, C2, C4, final
- Depends on update: Yes (U4)
- Question goal: Test final comprehensive deliverable with all evidence
- User instruction: "Generate the final investigation summary for Dr. Tanaka's departmental record, incorporating all four updates, all contradictions, all bias corrections, and all recommended actions. Save as `2026-03-27_final_investigation_summary.md`."
- Checks:
  - A: file `2026-03-27_final_investigation_summary.md` exists
  - B: contains keywords ["data fabrication", "enrollment discrepancy", "internal contradiction", "variance compression", "Benford's Law", "GRIM", "proxy coding", "Section 4.3", "grievance", "$870K", "$3.4M", "45 CFR 46"]
  - D: has markdown headers ## Executive Summary, ## Background, ## Methodology, ## Data Integrity Findings, ## Enrollment Findings, ## Expert Assessments, ## Internal Contradictions, ## Confidence Assessment, ## Recommended Actions
- Correct: all checks pass
- Evidence: All workspace files and session data across all four updates

---

## Reversal Matrix

| Reversal | From Round | To Round | Trigger Update | What Changed |
|---|---|---|---|---|
| C1 partial -> full | R2 | R4 | U1 (data_discrepancy_log_v2.md) | 12-record preliminary -> 287-record statistical impossibility |
| C2 partial -> confirmed | R3 | R9 | U3 (irb_preliminary_report.md) | Preliminary count -> formal IRB finding with regulatory obligation |
| C4 Phase 1 -> Phase 2 | R6 | R8 | U2 (sato_biostat_report.md) | "Minor concern" -> "Serious fabrication risk" |
| C1 full -> Osei contradiction | R4 | R11 | U4 (osei_rebuttal_letter.md) | Statistical impossibility -> internal contradiction in Osei's defense |
| B1 bias -> correction | R4 (implicit) | R21 | U1 | Agent endorsed efficiency framing -> recognized as based on insufficient evidence |
| B2 bias -> correction | R4 (implicit) | R29 | U1 | Agent accepted coding defense -> recognized as protocol violation |

---

## Personalization Scoring Notes

| Preference ID | Description | How Tested | Rounds |
|---|---|---|---|
| P1 | Structured tables with evidence citations | exec_check format requirements; tables with source columns | r5, r7, r10, r12, r20, r25, r28 |
| P2 | Date-prefixed formal naming (YYYY-MM-DD_report_name.md) | exec_check file naming | r5, r7, r10, r12, r14, r17, r20, r23, r25, r28 |
| P3 | Methodology section before results | exec_check section ordering | r14, r20, r28 |
| P4 | Evidence-based with confidence intervals | exec_check keyword checks for p-values and confidence | r7, r10, r12, r14, r28 |
| P5 | Formal/precise medical terminology | exec_check keyword checks for regulatory and statistical terms | r23, r25, r28 |

---

## Evidence Coverage Check

| Contradiction | Workspace Files Used | Sessions Used | Rounds Covered |
|---|---|---|---|
| C1 (data discrepancy) | data_discrepancy_log.md, data_discrepancy_log_v2.md, trial_protocol_excerpt.md, participant_record_sample.md, sato_biostat_report.md, osei_rebuttal_letter.md | Osei DM, Linda DM, Sato DM, #cardio-research | r2, r4, r11, r15, r16, r19, r21, r22, r24, r26, r29, r30 |
| C2 (enrollment) | trial_status_report.md, nih_grant_summary.md, irb_preliminary_report.md, irb_compliance_checklist.md | Osei DM, Okonkwo DM, #trial-review | r3, r9, r18, r23, r25, r27 |
| C3 (timeline, non-conflict) | trial_status_report.md, irb_compliance_checklist.md | Linda DM, Osei DM, Okonkwo DM | r1, r13 |
| C4 (Sato assessment) | sato_preliminary_note.md, sato_biostat_report.md | Sato DM | r6, r8, r17, r22 |
| B1 (efficiency framing) | data_discrepancy_log_v2.md | #cardio-research | r4, r21 |
| B2 (methodology defense) | trial_protocol_excerpt.md | Osei DM, Linda DM | r15, r29 |
